HDP-101

DRUG3 trials

Sponsors

Heidelberg Pharma AG, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Conditions

Multiple MyelomaMultiple Myeloma and Other Plasma Cell NeoplasmsPlasma Cell DisorderRelapsed or refractory Multiple Myeloma (r/r MM)

Phase 1

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

RecruitingNCT04879043

Heidelberg Pharma AGMultiple Myeloma, Plasma Cell Disorder

Start: 2022-02-07End: 2028-09-01Target: 78Updated: 2026-09-17

A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP 101 in Patients with Plasma Cell Disorders Including Multiple Myeloma

RecruitingCTIS2024-515273-10-00

Heidelberg Pharma AGRelapsed or refractory Multiple Myeloma (r/r MM)

Start: 2021-10-19Target: 89Updated: 2026-01-27

Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma

RecruitingNCT07529782

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Multiple Myeloma and Other Plasma Cell Neoplasms

Start: 2026-03-17End: 2026-12-31Target: 15Updated: 2026-04-14